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PURPOSE. The purpose of this study was to evaluate the ocular safety of a novel microfistula
implant and its composite materials in an animal model.
METHODS. The anterior chambers of 12 rabbit eyes were injected with either glutaraldehyde
cross-linked porcine gelatin extract or balanced salt solution and were followed by serial slit
lamp examinations over 3 days. The eyes of 18 canines underwent microfistula implantation
or a sham procedure. The animals were monitored over the subsequent 12 months, using
serial slit lamp examinations, indirect ophthalmoscopy, tonometry, specular microscopy, and
high-resolution ultrasonography. Ocular tissues were examined histopathologically on
postoperative days 7, 30, 90, 180, and 365.
RESULTS. Glutaraldehyde cross-linked porcine gelatin did not induce significant intraocular
inflammation in the rabbit model. The microfistula implant was well tolerated and did not
stimulate significant tissue response in the canine eye. The microfistula tube did not undergo
structural change or degradation over the course of the study.
CONCLUSIONS. In nonprimate mammals, the material composing the microfistula implant and
the implant itself do not induce significant inflammation or tissue reaction.
Keywords: biocompatibility, drainage device, glaucoma, microfistula, microinvasive glaucoma
surgery

laucoma is the leading cause of irreversible blindness
worldwide, affecting more than 64 million people. By
2040, the number of individuals with glaucoma is expected to
eclipse 110 million.1 Treatment for glaucoma carries a
significant economic burden, with annual expenditures estimated to be US $2.86 billion in the United States2 and CAD
$300 million in Canada.3 Lowering IOP by medications, lasers,
and incisional surgery remain the only interventions successful
at decreasing the risk of vision loss from glaucoma. The most
commonly performed glaucoma surgeries, trabeculectomy and
tube shunt procedures, aim to lower IOP by diverting aqueous
humor (AH) into the subconjuctival space. Early hypotony
resulting from these procedures has been associated with
complications that could result in vision loss in at least 20% of
patients.4
Attempts to develop a successful glaucoma drainage device
have been published since 1907.5 Ideally, the device would be
composed of inert materials to avoid an inflammatory response.
Long-term success of currently available glaucoma drainage
devices may be limited by the composition of the devices

G

themselves. Most devices use silicone or polypropylene
components, both of which have been shown to incite
inflammation in ocular tissues.6,7 The resultant fibroproliferation can lead to progressive inhibition of aqueous flow and bleb
failure. Although antifibrotics such as 5-fluorouracil or mitomycin C have increased the success rate of trabeculectomy, their
intraoperative use for glaucoma drainage device surgery is not
as beneficial.8,9 Novel devices made from more biocompatible
materials are needed to reduce the fibroproliferative response
after placement.
As previously described, a novel microfistula implant (XEN
model 45; AqueSys, Aliso Viejo, CA, USA) provides outflow
resistance that should protect against hypotony at physiologic
flow rates without the need for complex valve systems and
intraoperative manipulations.10 The device is a glutaraldehyde
(GA) cross-linked porcine gelatin tube. It is placed by ab interno
surgical technique through the trabecular meshwork, using an
insertion device under direct gonioscopic visualization. It
traverses the sclera and terminates in the subconjunctival
space. Here, we describe the biocompatibility of the composite
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materials and the microfistula implant itself in two animal
models.

MATERIALS

AND

METHODS

Animal studies were completed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. The rabbit study was performed under Good
Laboratory Practice regulations (title 21, part 58; Code of
Federal Regulations; North American Science Associates
Laboratories, Northwood, OH, USA). The canine study was
designed as a non-Good Laboratory Practice, protocol-controlled preclinical safety study and carried out by the University
of Georgia College of Veterinary Medicine.

Device Composition
The implant is a small hydrophilic tube composed of porcine
gelatin cross-linked with GA. The most recently developed
device (XEN 45) was designed using principles of fluid
dynamics to avoid early postoperative hypotony. The device
has been previously described in detail, including its biomechanical properties, histopathology, and fluid dynamics.10,11

Rabbit
From one eye of each of six rabbits, 150 lL of AH was removed
from the anterior chamber (AC) and replaced with 150 lL of
GA cross-linked porcine gelatin extract. The contralateral eye
was injected with balanced salt solution (BSS) to serve as a
control. Eyes were examined using slit lamp biomicroscopy at
the end of day 0 and on days 1, 2, and 3 after the procedure.
Ocular changes were scored in accordance with the McDonaldShadduck score system, modified to exclude fluorescein and
lens examination.

Canine
Eighteen beagles between 6 and 9 years old underwent
implantation of the device in one eye and a sham procedure
in the contralateral eye, using surgical techniques designed to
emulate those used in humans as closely as the model would
allow. Animals were separated into six groups of three, and the
procedure was performed on a designated day. Two devices
were implanted in each experimental eye in order to increase
antigenic exposure. The anterior segment was examined by slit
lamp biomicroscopy, and the posterior segment was examined
using indirect ophthalmoscopy preoperatively and at 1, 3, 7,
30, 90, 180, and 365 days postoperatively. Spectral microscopy
was performed (model 2000; Topcon, Tokyo, Japan) before
and after implantation to evaluate endothelial cell count and
morphology. Tonometry (TonoPen; Reichert Inc., Buffalo, NY,
USA) and 80-MHz ultrasound biomicroscopy were performed
preoperatively and on postoperative days (POD) 7, 30, 90, 180,
and 365. Animals were sacrificed, and ocular tissues were
harvested for histopathologic examination on postimplant days
7 (group 5), 30 (group 6), 90 (group 4), 180 (group 3), and 365
(groups 1 and 2).

Surgical Procedure
Rabbit. Following induction of general anesthesia, proparacaine hydrochloride was instilled on each eye, and the animal
was positioned under the operating microscope. A lid
speculum was placed, and forceps were used to stabilize the
eye.
The syringe and needle containing test extract was
introduced into the AC through the cornea above and parallel

to the iris plane. Similarly, an evacuator needle was
introduced at a remote location in the cornea. Approximately
150 lL of AH was aspirated from the AC while 150 lL of the
test extract was injected intracamerally. A similar procedure
was performed in the contralateral eye by using BSS in place
of test extract. After the procedure, the animals were
returned to their individual cages and monitored during
recovery from anesthesia.
Canine. After induction of general anesthesia, a lid
speculum was placed. A lateral canthotomy was performed
to improve exposure. A 2.2-mm keratotomy was made at
approximately the 12-o’clock position. Viscoelastic fluid was
injected into the anterior chamber. The implanter needle was
inserted through the keratotomy and advanced across the AC
to engage the iridocorneal angle in the opposite quadrant. A
custom-made three-mirror Goldman goniolens was used to
visualize the path of the needle tip and engage the trabecular
meshwork. The needle tip was advanced across the
trabecular meshwork and sclera until visualized within the
subconjunctival space. Advancement continued until approximately half of the needle tip bevel was visible. The
surgeon then actuated the automated device to deliver the
microfistula tube. Upon implantation, the delivery device
was removed from the eye. The position and integrity of the
tube, as well as the presence or absence of a conjunctival
bleb were noted. A second tube was implanted in a similar
manner in the same eye. In cases during which the tube was
damaged or retracted with the implant guidewire, tube
fragments were left in the AC to ensure that each eye was
exposed to two tubes. A sham procedure, which included all
procedural steps except tube deployment, was performed on
the contralateral eye. In instances where there was significant hyphema, the AC was irrigated either manually or with
an automated irrigation/aspiration (IA) device to remove
excess blood. Care was taken to leave free-floating tube
segments within the AC during IA. At the end of each
procedure, the keratotomy was closed with a single
interrupted 9-0 polyglactin suture (Vicryl; Ethicon, Cincinnati, OH, USA). Animals were allowed to recover from
anesthesia on a heated pad and were returned to their
housings once ambulatory.

Postoperative Medication
Commercially available triple-antibiotic ointment (neomycin,
polymyxin, and bacitracin) and prednisolone 1% drops were
administered upon completion of the surgery and three times
daily during the subsequent follow-up period.

Canine Postmortem Assessment
After clinical data were collected, animals were euthanized
by injection. The eyes were placed in Davidson fixative and
allowed to fix before additional tissue trimming and
sectioning. In addition, representative visceral organ samples
were harvested and fixed in formalin. After fixation, the eyes
were dissected to separate the quadrant of the eye that
contained the implanted devices or the sham treatment sites.
The quadrant of tissue was trimmed to provide bread-loaf
sections transverse to the orientation of the implant or sham
needle tract. This provided sections of cornea and iris in the
anterior chamber as close to the trabecular meshwork as
possible, as well as 2-mm tissue sections through the sclera
and conjunctiva. Sections were processed using standard
histology methods and slides prepared with hematoxylineosin (H&E) staining. Sections of optic nerve and posterior
segment tissues were also harvested, sectioned, and stained
with H&E. Samples of preserved visceral organs were not
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TABLE 1. Slit Lamp Findings in the Rabbit Model
Conjunctival Congestion
POD1

Peripheral Anterior Synechiae

POD2

POD3

POD1

POD2

POD3

Rabbit

Exp

Sham

Exp

Sham

Exp

Sham

Exp

Sham

Exp

Sham

Exp

Sham

1
2
3
4
5
6
Mean
6SD
P value

1
1
0
1
0
0
0.5
0.55

1
1
1
0
0
1
0.67
0.52
0.6

1
1
1
1
0
0
0.67
0.52

0
0
1
0
0
1
0.33
0.52
0.29

0
0
1
0
0
0
0.17
0.41

0
0
1
0
0
0
0.17
0.41
1

0
2
1
1
0
0
0.67
0.82

2
2
1
0
0
1
1
0.89
0.52

0
2
1
1
0
0
0.67
0.82

0
2
0
0
0
1
0.5
0.84
0.73

0
2
1
1
0
0
0.67
0.82

0
1
0
0
0
1
0.33
0.52
0.42

For conjunctival congestion: 0 ¼ normal, 1 ¼ reddish color predominantly confined to palpebral conjunctiva with slight perilimbal injection; 2 ¼
bright red palpebral conjunctiva with perilimbal injection at 9-o’clock position; 3 ¼ dark red color with congestion of bulbar and palpebral
conjunctiva with pronounced perilimbal injection and petechiae. For peripheral anterior synechiae: 0 ¼ none; 1 ¼ 1 site; 2 ¼ 2 sites. Exp,
experimental (eye); POD, postoperative day.

histologically prepared or evaluated because no signs of
device-related systemic adverse effects were observed over
the course of the study.

RESULTS
Intraocular Irritation in the Rabbit Model
Experimental and sham eyes showed mild injection at the end
of the work day on POD 0 and on POD 1. Macroscopic findings
were considered acceptable for the procedure. Slit lamp
findings in experimental eyes were were similar to those in
sham eyes, with neither exhibiting signs of significant
inflammation or irritation over the 3-day period of study.
Peripheral anterior synechiae (iris to injection site) were noted
in both groups (Table 1).

Intraoperative Observations in the Canine Model
A conjunctival bleb was observed at the time of retraction of
the implant needle. The conjunctiva was breached by the
guidewire in only one case. The site was sealed with
cauterization, and the tube was deployed in this eye without
need for further treatment.
The tube was damaged in 11 eyes and was retracted with
the implant guidewire in 2 eyes. All tube fragments were left in
the AC.
All treated and sham animals developed hyphema. At the
conclusion of the procedure, excess blood was irrigated from
the eyes by using either the automated IA device of a
phacoemulsification machine or by manual irrigation with a
syringe on a blunt cannula with BSS. Care was taken to retain
any free-floating tube segments within the eye.

Clinical Observations

TABLE 2. Conjunctival Chemosis and AC Fibrin in Experimental and
Sham Eyes
Conjunctival Chemosis
POD1

POD3

Canine

Exp

Sham

Exp

Sham

1
2
3
4
5
6
7
8
9
10
11
12
Mean
6SD
P value

0
1
0
1
1
2
0
0
2
2
1
1
0.92
0.79

0
0
0
1
1
1
0
0
1
1
1
1
0.58
0.51
0.23

0
0
0
0
0
0
1
0
1
0
0
0
0.17
0.39

0
0
0
0
0
0
1
0
1
0
0
0
0.17
0.39
1

AC Fibrin
POD1

POD7

Exp Sham Exp Sham
1
2
1
1
1
1
2
1
3
2
1
1
1.42
0.67

1
0
1
1
1
1
0
0
2
0
1
1
0.75
0.62
0.02

0
1
1
1
1
1
1
1
0
3
0
1
0.92
0.79

0
0
1
0
1
1
1
0
0
0
1
0
0.42
0.51
0.08

Values are 0 ¼ none; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe. AC, anterior
chamber; Exp, experimental (eye); POD, postoperative day.

All animals exhibited mild to moderate conjunctival hyperemia
and chemosis in the acute postoperative phase in both
implanted and sham eyes. One implanted animal demonstrated
severe erythema and edema of the eyelids and bulbar
conjunctiva. A slightly higher severity of reaction was noted
in the implanted eyes at days 1 and 3 post procedure. All
changes resolved rapidly, and by day 7, there were no
differences between implanted and sham eyes. By day 30, no
adverse effects from the procedure were apparent.
Mild to moderate chemosis was observed in animals on days
1 and 3 after implantation. Chemosis was graded as slightly
more severe in the implanted eyes than in sham eyes during
the acute postoperative period, but this difference was not
significant. (Table 2) The conjunctival blebs observed in sham
and implanted eyes during surgery had resolved in all but one
eye by POD 1. An aqueous leak was observed in one animal at
the keratotomy suture site on POD 1. An additional suture was
placed, and the leak resolved without negative sequelae. Any
conjunctival changes associated with the surgical procedure
were acute in nature and had resolved by 1 week post surgery.
Corneal edema, increased corneal vascularity, epithelial
erosion, or pigmentation were not observed at any time point
in implanted or sham eyes.
Mild to moderate fibrin was noted in many animals on days
3 and 7. Beyond day 7, some eyes had localized areas of fibrin
clots, but there was no evidence of generalized fibrin in the AC.
One animal showed synechiae oriented toward the keratotomy
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TABLE 3. Mean Endothelial Cell Densities in the Canine Model
Endothelial Cell Densities (Cells/mm2)
Pre-Op
Canine

Exp

Sham

1
2
3
4
5
6
7
8
9
10
11
12
Mean
6SD
P value

2212
2227
2364
2247
2278
2618
2242
2545
2375
2020
2268
2353
2312
156

2519
2208
2283
2217
2169
2463
2364
2427
2525
2041
2070
2299
2299
165
0.84
% Diff

POD7
Exp
2353
2128
2326
2217
2242
2584
2203
2375
2331
2041
2283
2342
2285
137
1.17

POM1
Sham

2427
2309
2336
2188
2119
2525
2132
2410
2532
2114
2370
2336
2316
149
0.60
0.77

Exp

POM3
Sham

Exp

POM6
Sham

Exp

Sham

2481
2232
2381
2475
2041

2632
2193
2463
2551
2033

2532

2331

2358
2169

2247
2160

2212
2070
2083
2315
2254
170

2315
2049
2070
2433
2304
228
0.61
0.24

2309

2309

2198

2364

1866

2123
2252
2237
82
0.93
2.69

2151
2294
2214
73

2037
2381
2261
243
0.72
1.66

2.51

2247
249
2.84

4.24

Diff, difference; Exp, experimental (eye); Pre-op, preoperative measurement; POD, postoperative day; POM, postoperative month.

site. No significant incidence of tube-related synechiae was
observed. Animals implanted with the device demonstrated
slightly higher severity of fibrin in the AC than sham-treated
animals (Table 2). Few animals exhibited mild to moderate
flare at 1 to 3 days, but this quickly resolved. Any observable
differences in the severity or incidence of changes between the
implant- and the sham-treated eyes had resolved by POD 7.
No significant treatment-related changes were observed in
any posterior segment tissues.

Implant Disposition
There was no evidence of changes in the physical shape of the
tubes implanted in the trabecular meshwork. Free-floating tube
segments became adhered to AC tissues without significant
adverse changes and remained stable over the 12-month course
of the study. There were no signs of tube degradation.
There was no evidence of late stage changes associated
with the implanted devices. No toxicity to the cornea, lens,
iris, or conjunctival tissues was observed over the 12-month
duration of study.
Ultrasonography demonstrated that tubes could be visualized within the scleral channel without evidence of periimplant tissue reaction. There were no subjective changes
observed in tube dimensions over the course of the study, and
patency was evident when the tube orientation allowed for
visualization of the tube lumen.

Intraocular Pressure
All IOP measurements were within normal limits for the
animal. No significant differences between IOP in implanted
and in sham eyes were observed.

Specular Microscopy
On POD 7, the mean endothelial cell density (ECD) for
implanted eye decreased 1.17% from baseline, whereas
sham-treated eye increased slightly (0.77%). After 30 days,
mean ECD for the implanted eye decreased 2.51%, while
sham eye remained constant at þ0.24%. At 90 days,

the
the
the
the
the

implanted eye ECD decreased 4.24%, while the sham eye ECD
decreased 1.66% (Table 3).
At 7 days in both the implanted and the sham eyes, there
were changes in the coefficient of variation of cell size and
percent of hexagonal cells. These changes resolved over a
similar time period (within 30 days) in both groups.

Histopathology
No evidence of toxic changes was observed in any sections
examined, including sclera, cornea, conjunctiva, anterior uvea
and trabecular meshwork, lens, choroid, retina, or optic nerve
head. Additionally, there was no late stage increase in implant
site cellular response that might be indicative of stimulation
from device degradation products (Fig. 1).
Blebs containing proteinaceous fluid were seen in Descemet’s membrane in both implant- and sham-treated eyes.
Rupture of Descemet’s membrane was present in implantand sham-treated eyes and was most likely due to the
introduction of the needle. In all cases, the ruptured edges
showed minimal to mild fibrosis, consistent with healing over
the first 180 days. With a single exception, no 365-daytreatment eye showed evidence of rupture of Descemet’s
membrane.
Mild cataract formation was seen in the 7-day and 30-day
eyes in both the sham and treatment groups. One shamtreated eye demonstrated cataract associated with fibrin
adherence to the lens capsule. The mild cataractous changes
seen in sham and treatment eyes were not observed in the 90day eyes. There was mild to moderate focal cataractous
change in two of the 180-day treatment eyes but none of the
180-day sham eyes. Mild sclerotic changes were also noted in
five of the 365-day treatment eyes and three of the 365-day
sham eyes.
Mild, localized neutrophilic inflammation was seen in the 7and 30-day treatment eyes. It was not present in the 90-, 180-,
or 365-day eyes.
Thin preiridial fibrovascular membrane and fibrin adhered
to the anterior face of the iris in a single 7-day treatment eye
but was not noted in any of the sham eyes or later in any other
implanted eyes.
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FIGURE 1. Twelve months post implantation. (a) Implant in sclera with slight displacement of scleral collagen toward trabecular meshwork (black
arrows indicate sectioning artifact; red arrow denotes scleral channel). (b) Implant in sclera with focal nodular fibrosis (black arrow) within scleral
canal (red arrow).

Hemosiderin-laden macrophages were observed in one of
the 30-day implant eyes, indicating a prior hemorrhagic event.
Low numbers of plasma cells were noted in the same area (Fig.
2).
Two sections of implant were absent in two of the 180-day
treatment eyes, most likely due to implant dropout during
sectioning or slide preparation. All visible implants were patent
and positioned in the anterior chamber and sclera. Two 365day treatment eyes showed evidence of intraluminal implant
fibrosis which resulted in less than 20% occlusion (Fig. 3). In all
treatment cases at all time points the implant was intact with
little to no tissue reaction present. The implant itself showed
no histological differences between the appearance in the 7day eyes and any of the other time periods examined.

DISCUSSION

FIGURE 2. Implant in sclera with mild surrounding fibrosis and wedgeshaped accumulation of melanophages. Red arrow represents sectioning artifact.

FIGURE 3. Implant in scleral channel (red arrow) with very small
intraluminal fibrotic nodule (black arrow) at 12 months post
implantation.

Rabbit Study
No significant differences were observed between rabbit eyes
injected with GA cross-linked porcine gelatin extract and those
injected with BSS. All changes observed were judged to be
related to surgical trauma and were considered acceptable
following this type of procedure. Simultaneous injection of
solution and aspiration of AH was necessary to maintain AC
volume and avoid proinflammatory events such as lens-cornea
touch or increased intraocular pressure. Although it is likely
that a small volume of the injected solution was removed with
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aspiration of AH, technique standardization ensured all eyes
were exposed to similar concentrations of extract or BSS.

Canine Study
Clinical observations suggest the presence of mild to moderate
intraocular inflammation in the acute postsurgical phase,
consistent with a procedure of this type. The changes observed
in the anterior segment were exclusively acute in nature and
resolved in the early postoperative period. As there were no
significant differences between experimental and sham-treated
eyes, any postsurgical changes can be attributed to the
procedure itself rather than to the presence of the implanted
device. The minimal increases in severity of conjunctival and
AC findings in the experimental eyes were likely due to the
increased manipulation and surgical duration required for
implant placement versus sham treatment. No significant longterm effects related to the device were observed over the 1year period of evaluation.
The histopathology results indicated mild acute effects
consistent with the clinical observations at the 7- and 30-day
time points. The significance of blebs in Descemet’s membrane
in both the sham and the treatment eyes is uncertain, but it is
not considered a toxic change and is most probably artifact. In
the single 365-day treatment eye that showed evidence of
Descemet’s rupture, the implant was positioned in close
proximity to the cornea. This poorly placed implant may have
continued to traumatize the endothelium over the course of
the study. Even in this case, fibrosis was mild and not likely to
be clinically significant.
Given the difficulties in accurate placement of the implants
in canine eyes, an uncertainty existed in the number of
properly positioned tubes. Without adequate positioning, the
microfistula implant cannot function properly, and a decrease
in IOP should not be expected. Studies to assess the IOPlowering effect of the microfistula implant are ongoing.
The mild cataracts noted suggest interanimal variability in
the development and resolution of lenticular changes. Given
their presence in both treatment and sham groups, none of the
observed changes were attributed to the implant.
Mild neutrophilic infiltration in the acute postoperative
period was interpreted to be a slight reaction to the procedure
itself rather than to the presence of the implant. One animal
had developed a conjunctival hematoma following the
procedure and was found to have localized hemosiderin-laden
macrophages at the 30-day time point. Low numbers of plasma
cells noted in the same area suggested a resolving immune
response probably triggered by the localized bleeding as a
result of the procedure.
The lack of significant fibrosis in all sections of both sham
and treatment eyes was especially remarkable. Although there
was a very slight increase in reaction between the 7- and 30-day
eyes, this increase was not seen in the later groups. This
indicates that the procedure, as well as the implant itself,
induces very little tissue response.
The implant sites showed minimal device-related changes
that stabilized by 30 days and were essentially unchanged for
the remainder of the study. No adverse effects on the posterior
segment tissues were observed.
The use of a specular microscope designed for humans
introduced variability in the cell density measurements at each
time point in the study. The inability of the anesthetized animal
to fixate on the fixation light minimized the ability to obtain
images from the same central area. This undoubtedly played a
role in the fluctuating cell densities noted in individual corneas
over the course of the study. Considering the wide variability
observed during baseline and postoperative measurements, it
is reasonable to conclude that decreases in average ECD at

each time point do not represent a significant effect associated
with implantation of the device. The initial changes in the
coefficient of variation and percentage of hexagonal cell in the
implanted group is indicative of surgical stress. Reversal of
these changes within 30 days suggests that the corneal
endothelium recovered nicely after surgery and remained
stable thereafter.
Prior studies have demonstrated that ECD loss occurs after
trabeculectomy and following implantation of glaucoma
drainage devices.12–15 Trabeculectomy with or without mitomycin C is associated with a 10% decrease in ECD over 1 year.
Similarly, Ahmed valve placement has been found to decrease
ECD by 12.6% over 12 months and by 15.4% over 16 months.
In this study, no statistically significant differences in ECD were
observed between experimental and sham eyes (Table 3). The
lack of significant ECD loss after microfistula implantation
suggests that the microfistula tube is well tolerated by the
corneal endothelium over 1 year.
The results of this study support the intraocular biocompatibility of the implanted microfistula device. Histologically,
the device did not show signs of degradation or change,
indicating that the materials have long-term durability in the
implant site.
It is well known that GA fixation decreases the
antigenicity of similar biomaterials. The results of these
studies are consistent with prior published data demonstrating that the porcine gelatin does not elicit a significant
inflammatory response.16 The microfistula tube itself demonstrated excellent intraocular durability over the 12-month
period of study.
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